Repository logo
 
Publication

Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on electronic health records

2023Journal article Open access
Simple item page
dc.contributor.authorKislaya, Irina
dc.contributor.authorPeralta‐Santos, André
dc.contributor.authorBorges, Vítor
dc.contributor.authorVieira, Luís
dc.contributor.authorSousa, Carlos
dc.contributor.authorFerreira, Bibiana
dc.contributor.authorPelerito, Ana
dc.contributor.authorGomes, João Paulo
dc.contributor.authorLeite, Pedro Pinto
dc.contributor.authorNunes, Baltazar
dc.contributor.authorMachado, Ausenda
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorPeixoto, Vasco Ricoca
dc.contributor.authorCasaca, Pedro
dc.contributor.authorFernandes, Eugenia
dc.contributor.authorRodrigues, Eduardo
dc.contributor.authorFerreira, Rita
dc.contributor.authorIsidro, Joana
dc.contributor.authorPinto, Miguel
dc.contributor.authorDuarte, Sílvia
dc.contributor.authorSantos, Daniela
dc.contributor.authorMeneses, Luís
dc.contributor.authorAlmeida, José Pedro
dc.contributor.authorMatias, Ana
dc.contributor.authorFreire, Samanta
dc.contributor.authorGrilo, Teresa
dc.date.accessioned2023-04-11T10:30:46Z
dc.date.available2023-04-11T10:30:46Z
dc.date.issued2023
dc.description.abstractBackground: Information on vaccine effectiveness in a context of novel variants of concern (VOC) emergence is of key importance to inform public health policies. This study aimed to estimate a measure of comparative vaccine effectiveness between Omicron (BA.1) and Delta (B.1.617.2 and sub-lineages) VOC according to vaccination exposure (primary or booster). Methods: We developed a case–case study using data on RT-PCR SARS-CoV2-positive cases notified in Portugal during Weeks 49–51, 2021. To obtain measure of comparative vaccine effectiveness, we compared the odds of vaccination in Omicron cases versus Delta using logistic regression adjusted for age group, sex, region, week of diagnosis, and laboratory of origin. Results: Higher odds of vaccination were observed in cases infected by Omicron VOC compared with Delta VOC cases for both complete primary vaccination (odds ratio [OR] = 2.1; 95% confidence interval [CI]: 1.8 to 2.4) and booster dose (OR = 5.2; 95% CI: 3.1 to 8.8), equivalent to reduction of vaccine effectiveness from 44.7% and 92.8%, observed against infection with Delta, to 6.0% (95% CI: 29.2% to 12.7%) and 62.7% (95% CI: 35.7% to 77.9%), observed against infection with Omicron, for complete primary vaccination and booster dose, respectively. Conclusion: Consistent reduction in vaccine-induced protection against infection with Omicron was observed. Complete primary vaccination may not be protective against SARS-CoV-2 infection in regions where Omicron variant is dominant.pt_PT
dc.description.sponsorshipGrant no. 2021/PHF/23776; POCI-01-0145-FEDER-022184; Project ALG-D2-2021-06pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.1111/irv.13121pt_PT
dc.identifier.issn1750-2640
dc.identifier.urihttp://hdl.handle.net/10400.1/19428
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherWileypt_PT
dc.relation2021/PHF/23776pt_PT
dc.relationComprehensive Health Research Center - Research, Education, Training and Innovation in Clinical research and Public Health
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectCase–case designpt_PT
dc.subjectCOVID-19pt_PT
dc.subjectDelta variantpt_PT
dc.subjectOmicron variantpt_PT
dc.subjectSARS-CoV-2pt_PT
dc.subjectVaccineeffectivenesspt_PT
dc.titleComparative complete scheme and booster effectiveness of COVID‐19 vaccines in preventing SARS‐CoV‐2 infections with SARS‐CoV‐2 Omicron (BA.1) and Delta (B.1.617.2) variants: A case–case study based on electronic health recordspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleComprehensive Health Research Center - Research, Education, Training and Innovation in Clinical research and Public Health
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04923%2F2020/PT
oaire.citation.issue3pt_PT
oaire.citation.titleInfluenza and Other Respiratory Virusespt_PT
oaire.citation.volume17pt_PT
oaire.fundingStream6817 - DCRRNI ID
person.familyNameferreira
person.givenNameBibiana
person.identifier.ciencia-idA311-E925-09C5
person.identifier.orcid0000-0003-4772-9395
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationc928b692-bf43-4e45-929b-cba3517a966d
relation.isAuthorOfPublication.latestForDiscoveryc928b692-bf43-4e45-929b-cba3517a966d
relation.isProjectOfPublication7001a3f9-4045-4e20-a0ea-3acd691b4632
relation.isProjectOfPublication.latestForDiscovery7001a3f9-4045-4e20-a0ea-3acd691b4632

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Influenza Resp Viruses - 2023 - Kislaya - Comparative complete scheme and booster effectiveness of COVID‐19 vaccines in.pdf
Size:
962.34 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
3.46 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ABC2-Artigos (em revistas ou actas indexadas)
FCB2-Artigos (em revistas ou actas indexadas)